Related Experiment Video
Updated: Apr 5, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE
Jean-Philippe Collet1, Jean-Sébastien Hulot1, Thomas Cuisset2
1ACTION Study Group, Institut de Cardiologie, INSERM_UMRS 1166, Pitié-Salpêtrière Hospital (APHP), Sorbonne Universités UPMC (Paris 6), Paris, France.
Insights
Genetic testing for clopidogrel metabolism (CYP2C19 genotype) effectively identified poor responders but did not improve clinical outcomes in patients undergoing stent implantation. This suggests genetic information alone is insufficient for guiding antiplatelet therapy adjustments.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Clinical Pharmacology
Background:
- The ARCTIC study evaluated platelet function monitoring for antiplatelet therapy adjustment in 2440 patients undergoing stent implantation.
- No significant clinical outcome improvement was observed with platelet function monitoring compared to conventional strategies.
Purpose of the Study:
- To investigate the association between CYP2C19 genotypes, clopidogrel's pharmacodynamic response, and clinical outcomes in patients receiving antiplatelet therapy.
- To determine if CYP2C19 genetic variations predict clopidogrel response and subsequent clinical events.
Main Methods:
- The ARCTIC-GENE study genotyped 1394 patients for CYP2C19 loss- and gain-of-function alleles.
- Patients were categorized as slow or rapid metabolizers based on their CYP2C19 genotype.
- Treatment strategies were compared between slow and rapid metabolizers, with adjustments based on platelet function.
Main Results:
- Slow metabolizers (n=459) were more frequent poor responders to clopidogrel at randomization and 14 days post-treatment compared to rapid metabolizers (n=935).
- Despite differences in response, intensification of antiplatelet treatment did not vary between groups based on the study algorithm.
- No significant difference was observed in the primary composite clinical outcome (death, MI, stent thrombosis, stroke, revascularization) or safety outcomes between slow and rapid metabolizers at 1 year.
Conclusions:
- CYP2C19 genotype accurately predicted clopidogrel pharmacodynamic response but did not correlate with clinical outcomes.
- Genetic information alone provided limited added value to pharmacodynamic monitoring for adjusting antiplatelet therapy in this study.
- The findings suggest that while genetic profiling identifies response variability, its direct impact on clinical outcomes needs further investigation in guiding antiplatelet therapy.
Background:
The ARCTIC study randomized 2440 patients scheduled for stent implantation to a strategy of platelet function monitoring with drug adjustment in patients who had a poor response to antiplatelet therapy or to a conventional strategy without monitoring and drug adjustment. No significant improvement in clinical outcomes with platelet function monitoring was observed.
Objective:
The purpose of this study is to assess the relationships between CYP2C19 genotypes, clopidogrel pharmacodynamic response, and clinical outcome.
Methods And Results:
In the ARCTIC-GENE study, 1394 patients were genotyped for loss- and gain-of-function CYP2C19 alleles. Randomization of treatment strategy was well balanced. Slow metabolizers identified as carriers of at least one loss-of-function allele CYP2C19*2 (n = 459) were more likely poor responders at randomization (41.6 vs. 31.6%, p = 0.0112) and 14 days later (23.8 vs. 10.4%, p < 0.0001) and more frequently on prasugrel (11.5 vs. 8.1%, p = 0.039) as compared with rapid metabolizers (n = 935). Intensification of antiplatelet treatment did not differ between slow and rapid metabolizers according to the study algorithm based on platelet function only. The primary study outcome defined as the composite of death, myocardial infarction, stent thrombosis, stroke, or urgent revascularization 1 year after stent implantation did not differ between slow and rapid metabolizers (HR 0.988, 95% CI [0.812;1.202], p = 0.90). Likewise, the primary safety outcome did not differ between rapid and slow metabolizer phenotype.
Conclusions:
The genetic clopidogrel profile was a good marker of platelet function response on clopidogrel but was not related to clinical outcome suggesting that the genetic added little to the pharmacodynamic information used in the study to adjust antiplatelet therapy. ClinicalTrials.gov: NCT00827411.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:28Cardiac Catheterization I: Pre-Procedure Overview
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...